View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 21, 2021updated 12 Jul 2022 11:06am

Better data collection and convenience for remote monitoring of patients the main benefits of using digital health technologies in clinical trials: Poll

The onset of COVID-19 pandemic has severely disrupted the ongoing clinical research and trials forcing pharmaceutical companies to adopt digital technologies to ensure the safety of patients and clinicians.

Digital technologies are expected to be used in clinical trials even post the pandemic due to the benefits they offer.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

In a poll Verdict has conducted to assess the main benefits of using digital health technologies in clinical trials, a majority 45% of the respondents opined that digital clinical trials improve data collection (24%) and enable the remote monitoring of patients (21%).

Cost-saving was considered as the main benefit by 17% of the respondents, while continuous and passive monitoring of patients was voted by 14% of the respondents.

Improved patient retention, patient recruitment and reduced burden on staff were voted as the main benefits by a lesser 10%, 9% and 5% of the respondents, respectively.

Better data collection and convenience for remote monitoring of patients the main benefits of using digital health technologies in clinical trials

The analysis is based on 189 responses received from the readers of Clinical Trials Arena, a Verdict network site, between 08 February and 18 May 2021.

Benefits offered by digital health technologies in clinical trials

The traditional approach to conducting clinical trials no longer seems feasible especially in the face of unforeseen incidents such as the COVID-19 pandemic. Patient enrolment is the biggest challenge in clinical trials, which was compounded by the pandemic causing more than 58% of clinical trials to be disrupted as of June 2021, according to GlobalData.

Life sciences companies are increasingly adopting digital health technologies such as wearables, sensors and other digital devices to conduct virtual or decentralised clinical trials and address these issues. Digital health technologies provide patients with the autonomy to participate in a trial remotely thereby improving participation and retention.

Digital technologies can also enable better patient monitoring by collecting data passively in real-time and providing a holistic view of a patient’s health in addition to understanding treatment response. Furthermore, they enable cost reduction and minimise risk to subjects, while maintaining trial timelines.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena